SCHEMBL2835649

SCHEMBL2835649

CON(C)C(=O)C(NC(=O)OC(C)(C)C)c1ccc(Cl)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 3/20 0.43
JAK3 P52333 1/20 0.40
BTK Q06187 1/20 0.40
KDM4D Q6B0I6 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP3A5 P20815 2/20 0.39
MDM2 Q00987 1/20 0.38
TRPA1 O75762 2/20 0.37
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
PKM P14618 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36
CTSL P07711 1/20 0.35
S1PR1 P21453 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833785 0.83 S1PR3 (0.50) S1PR3KDM4DCYP3A4CYP3A5MDM2
SCHEMBL2834038 0.81 S1PR3 (0.45) S1PR3JAK3BTKTRPA1PPARG
SCHEMBL14847752 0.81 S1PR3 (0.45) S1PR3JAK3BTKTRPA1PPARG
SCHEMBL14847753 0.81 S1PR3 (0.45) S1PR3JAK3BTKTRPA1PPARG
SCHEMBL2833348 0.80 S1PR3 (0.41) S1PR3JAK3BTKTRPA1PKM
SCHEMBL268969 0.80 JAK3 (0.46) S1PR3JAK3BTKPPARGPPARA
SCHEMBL269021 0.78 JAK3 (0.47) JAK3BTKPPARGPPARAPKM
SCHEMBL22862543 0.78 JAK3 (0.45) S1PR3JAK3BTKTRPA1MAPT
SCHEMBL2833955 0.77 MDM2 (0.50) S1PR3KDM4DCYP3A4CYP3A5MDM2
SCHEMBL2837601 0.76 JAK3 (0.40) S1PR3JAK3BTKTRPA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885JAK3 3843/4885BTK 1832/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885JAK3 3843/4885BTK 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.